380 related articles for article (PubMed ID: 12843221)
1. rhTSH stimulation before radioiodine therapy in thyroid cancer reduces the effective half-life of (131)I.
Menzel C; Kranert WT; Döbert N; Diehl M; Fietz T; Hamscho N; Berner U; Grünwald F
J Nucl Med; 2003 Jul; 44(7):1065-8. PubMed ID: 12843221
[TBL] [Abstract][Full Text] [Related]
2. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.
Hänscheid H; Lassmann M; Luster M; Thomas SR; Pacini F; Ceccarelli C; Ladenson PW; Wahl RL; Schlumberger M; Ricard M; Driedger A; Kloos RT; Sherman SI; Haugen BR; Carriere V; Corone C; Reiners C
J Nucl Med; 2006 Apr; 47(4):648-54. PubMed ID: 16595499
[TBL] [Abstract][Full Text] [Related]
3. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
Luster M; Lippi F; Jarzab B; Perros P; Lassmann M; Reiners C; Pacini F
Endocr Relat Cancer; 2005 Mar; 12(1):49-64. PubMed ID: 15788638
[TBL] [Abstract][Full Text] [Related]
4. Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients.
Pötzi C; Moameni A; Karanikas G; Preitfellner J; Becherer A; Pirich C; Dudczak R
Clin Endocrinol (Oxf); 2006 Oct; 65(4):519-23. PubMed ID: 16984246
[TBL] [Abstract][Full Text] [Related]
5. Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study.
Taïeb D; Sebag F; Cherenko M; Baumstarck-Barrau K; Fortanier C; Farman-Ara B; De Micco C; Vaillant J; Thomas S; Conte-Devolx B; Loundou A; Auquier P; Henry JF; Mundler O
Clin Endocrinol (Oxf); 2009 Jul; 71(1):115-23. PubMed ID: 18803678
[TBL] [Abstract][Full Text] [Related]
6. Coming of age: recombinant human thyroid-stimulating hormone as a preparation for (131)i therapy in thyroid cancer.
Robbins RJ; Pentlow KS
J Nucl Med; 2003 Jul; 44(7):1069-71. PubMed ID: 12843222
[No Abstract] [Full Text] [Related]
7. Dosimetry of radioiodine therapy in patients with nodular goiter after pretreatment with a single, low dose of recombinant human thyroid-stimulating hormone.
Nieuwlaat WA; Hermus AR; Ross HA; Buijs WC; Edelbroek MA; Bus JW; Corstens FH; Huysmans DA
J Nucl Med; 2004 Apr; 45(4):626-33. PubMed ID: 15073259
[TBL] [Abstract][Full Text] [Related]
8. Age influences TSH serum levels after withdrawal of l-thyroxine or rhTSH stimulation in patients affected by differentiated thyroid cancer.
Montesano T; Durante C; Attard M; Crocetti U; Meringolo D; Bruno R; Tumino S; Rubello D; Al-Nahhas A; Colandrea M; Maranghi M; Travascio L; Ronga G; Torlontano M
Biomed Pharmacother; 2007 Sep; 61(8):468-71. PubMed ID: 17553654
[TBL] [Abstract][Full Text] [Related]
9. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal.
Tuttle RM; Brokhin M; Omry G; Martorella AJ; Larson SM; Grewal RK; Fleisher M; Robbins RJ
J Nucl Med; 2008 May; 49(5):764-70. PubMed ID: 18413378
[TBL] [Abstract][Full Text] [Related]
10. Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer.
Freudenberg LS; Frömke C; Petrich T; Marlowe RJ; Koska WW; Brandau W; Eising EG; Knust EJ; Bockisch A; Jentzen W
Exp Clin Endocrinol Diabetes; 2010 Jul; 118(7):393-9. PubMed ID: 19856257
[TBL] [Abstract][Full Text] [Related]
11. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human thyroid-stimulating hormone (rhTSH) in the radioablation of well-differentiated thyroid cancer: preliminary therapeutic experience.
Perros P
J Endocrinol Invest; 1999; 22(11 Suppl):30-4. PubMed ID: 10727003
[TBL] [Abstract][Full Text] [Related]
13. Thyroid Uptake and Effective Half-Life of Radioiodine in Thyroid Cancer Patients at Radioiodine Therapy and Follow-Up Whole-Body Scintigraphy Either in Hypothyroidism or Under rhTSH.
Bacher R; Hohberg M; Dietlein M; Wild M; Kobe C; Drzezga A; Schmidt M
J Nucl Med; 2019 May; 60(5):631-637. PubMed ID: 30315143
[TBL] [Abstract][Full Text] [Related]
14. Overview on the use of recombinant human thyrotropin in thyroid cancer of follicular cell origin.
Zanotti-Fregonara P; Toubert ME; Taieb D; Ravasi L; Rubello D; Hindie E
Minerva Endocrinol; 2008 Jun; 33(2):53-65. PubMed ID: 18332849
[TBL] [Abstract][Full Text] [Related]
15. How the availability of recombinant human TSH has changed the management of patients who have thyroid cancer.
Schlumberger M; Ricard M; De Pouvourville G; Pacini F
Nat Clin Pract Endocrinol Metab; 2007 Sep; 3(9):641-50. PubMed ID: 17710085
[TBL] [Abstract][Full Text] [Related]
16. The role of recombinant thyroid-stimulating hormone (rhTSH) in the detection and management of well-differentiated thyroid carcinoma: a roundtable discussion.
Schlumberger MJ; Incerti C; Pacini F; Reiners C
J Endocrinol Invest; 1999; 22(11 Suppl):35-41. PubMed ID: 10727004
[TBL] [Abstract][Full Text] [Related]
17. Stimulation test in the follow-up of thyroid cancer: plasma rhTSH levels are dependent on body weight, not endogenously stimulated TSH values.
Zanotti-Fregonara P; Duron F; Keller I; Khoury A; Devaux JY; Hindié E
Nucl Med Commun; 2007 Apr; 28(4):257-9. PubMed ID: 17325587
[TBL] [Abstract][Full Text] [Related]
18. Recombinant thyroid-stimulating hormone in differentiated thyroid cancer.
Krausz Y; Uziely B; Nesher R; Chisin R; Glaser B
Isr Med Assoc J; 2001 Nov; 3(11):843-9. PubMed ID: 11729583
[TBL] [Abstract][Full Text] [Related]
19. High prevalence of side effects after recombinant human thyrotropin-stimulated radioiodine treatment with 30 mCi in patients with multinodular goiter and subclinical/clinical hyperthyroidism.
Romão R; Rubio IG; Tomimori EK; Camargo RY; Knobel M; Medeiros-Neto G
Thyroid; 2009 Sep; 19(9):945-51. PubMed ID: 19678745
[TBL] [Abstract][Full Text] [Related]
20. Radioiodine 131I treatment for large nodular goiter: recombinant human thyrotropin allows the reduction of radioiodine 131I activity to be administered in patients with low uptake.
Ceccarelli C; Antonangeli L; Brozzi F; Bianchi F; Tonacchera M; Santini P; Mazzeo S; Bencivelli W; Pinchera A; Vitti P
Thyroid; 2011 Jul; 21(7):759-64. PubMed ID: 21568727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
